Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
J Ophthalmol ; 2015: 914098, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-26075087

RESUMO

Purpose. The pathogenesis of pseudoexfoliation (PEX), the most common cause of secondary glaucoma, has not been clearly identified, but there is increasing evidence that points out the role of oxidative stress. The aim of this study is to evaluate some of the most commonly used blood parameters, hemoglobin (Hb), red blood cell count (RBC), alanine aminotransferase (ALT), and uric acid (UA) levels, in subjects with PEX. Materials and Methods. This study is performed in a state hospital between November 2011 and December 2012. Retrospective chart review of subjects who underwent cataract surgery was performed. Thirty-one healthy subjects with PEX and 34 healthy subjects without PEX were evaluated. Hb, RBC, ALT, and UA levels were recorded. Student's t-test was used to compare the two groups. Results. The mean age was 73.6 ± 14.1 years in PEX group and 70.1 ± 12.7 in control group (p = 0.293). Hb, RBC, ALT, and UA levels did not show a statistically significant difference among PEX and control groups (p > 0.05 for all). Conclusion. Serum levels of Hb, RBC, ALT, and UA levels were similar in subjects with and without PEX. Further studies are needed to clarify the precise role of Hb, RBC, ALT, and UA in the pathogenesis of PEX.

2.
J Ocul Pharmacol Ther ; 30(8): 650-6, 2014 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-24983781

RESUMO

PURPOSE: To evaluate the inhibitory effects of propranolol, a nonselective and lipophilic ß-adrenergic receptor blocker, on alkali-induced corneal neovascularization (NV). METHODS: Corneal NV was induced in 24 eyes of 24 Wistar rats using NaOH. Following alkali burn, animals were randomized into 4 groups according to topical treatment. Group I received 0.9% NaCl, Group II received preservative-free dexamethasone sodium phosphate 1 mg/mL, Group III received propranolol hydrochloride 1 mg/mL, and Group IV received 0.5 mg/mL propranolol hydrochloride drops twice a day for 7 days. The inhibitory effects of the drugs were compared as the percent areas of cornea covered by NV. Anti-vascular endothelial growth factor (VEGF) and anti-active caspase-3 immunostainings were also performed in corneal sections. RESULTS: The median percent area of corneal NV was 59% (40.3-65.6) in Group I, 25.5% (20.9-43.4) in Group II, 68.9% (36.7-78.0) in Group III, and 50.4% (42.2-63.3) in Group IV. Group III and IV did not show any difference in comparison to Group I. Group II showed a statistically significant smaller area of corneal NV compared with Group I, III, and IV (P=0.004 for each comparison). Anti-VEGF immunostaining was significantly less in Group II compared with the other groups. Anti-active caspase-3 immunostaining was not different among the treatment groups. CONCLUSIONS: Topical propranolol 1 or 0.5 mg/mL does not have a significant inhibitory effect on alkali-induced corneal NV in rats.


Assuntos
Antagonistas Adrenérgicos beta/uso terapêutico , Neovascularização da Córnea/tratamento farmacológico , Propranolol/uso terapêutico , Antagonistas Adrenérgicos beta/administração & dosagem , Antagonistas Adrenérgicos beta/farmacologia , Animais , Queimaduras Químicas/complicações , Caspase 3/metabolismo , Cáusticos/farmacologia , Neovascularização da Córnea/induzido quimicamente , Neovascularização da Córnea/metabolismo , Dexametasona/administração & dosagem , Dexametasona/uso terapêutico , Modelos Animais de Doenças , Relação Dose-Resposta a Droga , Queimaduras Oculares/induzido quimicamente , Queimaduras Oculares/complicações , Glucocorticoides/administração & dosagem , Glucocorticoides/uso terapêutico , Instilação de Medicamentos , Masculino , Propranolol/administração & dosagem , Propranolol/farmacologia , Ratos Wistar , Hidróxido de Sódio/farmacologia , Resultado do Tratamento , Fator A de Crescimento do Endotélio Vascular/metabolismo
3.
Int J Ophthalmol ; 7(2): 220-5, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-24790861

RESUMO

AIM: To evaluate the inhibitory effects of regorafenib (BAY 73-4506), a multikinase inhibitor, on corneal neovascularization (NV). METHODS: Thirty adult male Sprague-Dawley rats weighing 250-300 g, were used. Corneal NV was induced by NaOH in the left eyes of each rat. Following the establishment of alkali burn, the animals were randomized into five groups according to topical treatment. Group 1 (n = 6) received 0.9% NaCl, Group 2 (n = 6) received dimethyl sulfoxide, Group 3 (n = 6) received regorafenib 1 mg/mL, Group 4 (n =6) received bevacizumab 5 mg/mL and Group 5 (n = 6) received 0.1% dexamethasone phosphate. On the 7d, the corneal surface covered with neovascular vessels was measured on photographs as the percentage of the cornea's total area using computer-imaging analysis. The corneas obtained from rats were semiquantitatively evaluated for caspase-3 and vascular endothelial growth factor by immunostaining. RESULTS: A statistically significant difference in the percent area of corneal NV was found among the groups (P <0.001). Although the Group 5 had the smallest percent area of corneal NV, there was no difference among Groups 3, 4 and 5 (P >0.005). There was a statistically significant difference among the groups in apoptotic cell density (P = 0.002). The staining intensity of vascular endothelial growth factor in the epithelial and endothelial layers of cornea was significantly different among the groups (P <0.05). The staining intensity of epithelial and endothelial vascular endothelial growth factor was significantly weaker in Groups 3, 4 and 5 than in Groups 1 and 2. CONCLUSION: Topical administration of regorafenib 1 mg/mL is partly effective for preventing alkali-induced corneal NV in rats.

4.
J Ocul Pharmacol Ther ; 29(10): 893-9, 2013 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-24070366

RESUMO

PURPOSE: We aimed to compare the efficacy of topical daptomycin (DAP) with that of vancomycin (VA) in the treatment of keratitis caused by methicillin-resistant Staphylococcus aureus (MRSA). METHODS: One hundred colony-forming unit MRSA bacteria were injected intrastromally into both corneas of 28 rabbits. Sixteen hours after injection, the rabbits' eyes were treated with 1 drop of topical DAP (10 or 50 mg/mL), VA (50 mg/mL), or isotonic saline for 19 doses. Their eyes were examined for clinical severity before and after treatment. RESULTS: The minimum inhibitory concentration values of VA and DAP against the bacterial strain were found to be 2 and 0.5 µg/mL, respectively. The mean pre- and post-treatment clinical scores of the eyes did not differ significantly among the groups. However, the mean difference between the post- and pretreatment clinical scores was significantly lower in the 50 mg/mL DAP group than in the other groups (P=0.042). A marked decrease in bacterial load was detected in all treatment groups compared to the control group (P=0.002). Although there were no significant differences in bacterial load among the treatment groups, the 50 mg/mL DAP group showed the greatest decrease. The mean % epithelial erosion rate tended to be higher in the 50 mg/mL VA group than in the other groups (P=0.31). CONCLUSIONS: Topical DAP significantly reduced the bacterial load and showed activity against MRSA comparable to that of fortified VA in this experimental model.


Assuntos
Antibacterianos/farmacologia , Daptomicina/farmacologia , Ceratite/tratamento farmacológico , Infecções Estafilocócicas/tratamento farmacológico , Administração Oftálmica , Animais , Antibacterianos/administração & dosagem , Carga Bacteriana/efeitos dos fármacos , Contagem de Colônia Microbiana , Daptomicina/administração & dosagem , Modelos Animais de Doenças , Relação Dose-Resposta a Droga , Infecções Oculares Bacterianas/tratamento farmacológico , Infecções Oculares Bacterianas/microbiologia , Ceratite/microbiologia , Masculino , Staphylococcus aureus Resistente à Meticilina/isolamento & purificação , Testes de Sensibilidade Microbiana , Soluções Oftálmicas , Coelhos , Infecções Estafilocócicas/microbiologia , Vancomicina/administração & dosagem , Vancomicina/farmacologia
5.
Graefes Arch Clin Exp Ophthalmol ; 251(11): 2555-61, 2013 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-24048578

RESUMO

BACKGROUND: We aimed to study the inhibitory effects of topical cyclosporine A (CsA) 0.05% on immune-mediated corneal neovascularization, and to compare its efficacy with those of dexamethasone 0.1% and bevacizumab 0.5%. METHODS: Immune-mediated corneal neovascularization was created in 36 right eyes of 36 rabbits. The rabbits were then randomized into four groups. Group I received CsA 0.05%, Group II received dexamethasone 0.1%, Group III received bevacizumab 0.5%, and Group IV received isotonic saline twice a day for 14 days. The corneal surface covered with neovascular vessels was measured on the photographs. The rabbits were then sacrificed and the corneas excised. Paraffin-embedded sections were stained with hematoxylin-eosin and terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling assay. RESULTS: The means of percent area of corneal neovascularization in Group I, II, III, and IV were 24.4%, 5.9%, 37.1%, and 44.1%, respectively. The inhibitory effect of CsA 0.05% was found to be better than the effect found in the bevacizumab 0.5% and control groups (p = 0.03 and p = 0.02, respectively). CsA 0.05% was found to have significantly lesser inhibitory effects on corneal neovascularization than dexamethasone 0.1% (p < 0.001). Apoptotic cell density was higher in Group III and Group IV than in Group I and Group II. There was no difference between Group I and Group II in terms of apoptotic cell density (p = 0.7). CONCLUSIONS: Topical CsA 0.05% was shown to have an inhibitory effect on immune-mediated corneal neovascularization in rabbits.


Assuntos
Neovascularização da Córnea/tratamento farmacológico , Ciclosporina/administração & dosagem , Imunossupressores/administração & dosagem , Administração Tópica , Inibidores da Angiogênese/administração & dosagem , Animais , Anticorpos Monoclonais Humanizados/administração & dosagem , Apoptose , Reação de Arthus/tratamento farmacológico , Reação de Arthus/imunologia , Bevacizumab , Biotina/análogos & derivados , Neovascularização da Córnea/imunologia , Nucleotídeos de Desoxiuracil , Dexametasona/administração & dosagem , Modelos Animais de Doenças , Glucocorticoides/administração & dosagem , Técnicas Imunoenzimáticas , Marcação In Situ das Extremidades Cortadas , Soluções Oftálmicas , Coelhos , Soroalbumina Bovina/imunologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA